

PREPARATION AND CHARACTERIZATION OF SOLID DISPERSION OF MODAFINIL FOR IMPROVEMENT OF DISSOLUTION PROFILE

VYAS JIGAR^{1*}, PATEL JAYVADAN², JAIN D. A.¹

¹Department of Pharmaceutics, Bhagwant University, Ajmer, India, ²Nootan Pharmacy College, Visnagar, Gujarat, India.
Email: drjrvyas@yahoo.co.in

Received: 06 Aug 2012, Revised and Accepted: 20 Sep 2012

ABSTRACT

Solid dispersions of Modafinil were prepared using polyethyleneglycols, in various proportions by melting, solvent evaporation and simple mixing method. Based on the solubility and melting point study, PEG8000 was selected and solid dispersion batch F9 containing drug:PEG8000 in 1:4 was formulated as tablet (batch TF9) and evaluated for *in-vitro* drug dissolution and six month stability. The results were compared with that of tablet containing physical mixture of drug:PEG8000 in the same ratio (batch TF27) and conventional tablet containing plain Modafinil (batch CT). Tablet TF9 has shown significant improvement of dissolution profile of Modafinil when compared with that of tablet TF27 and CT. Present study conclusively demonstrated that PEG8000 enhanced water solubility of Modafinil by amorphisation, which was confirmed by XRPD and FTIR. The melting method was found better than solvent evaporation method for enhancement of dissolution profile.

Keywords: Modafinil, Solubility enhancement solid dispersion, Polyethyleneglycols,

INTRODUCTION

Many potential drug candidates are characterized by a low oral bioavailability. Often, poor drug dissolution/solubility rather than limited permeation through the epithelia of the gastrointestinal tract are responsible for low oral bioavailability. The relationship between dissolution rate and absorption is particularly distinct when considering drugs of low solubility. Consequently, numerous attempts have been made to modify the dissolution characteristics of certain drugs in an effort to attain more rapid and more complete absorption. Among the techniques to increase aqueous solubility/dissolution rate, solid dispersion is one of the most popular techniques^{1, 2}, although few marketed products rely on this concept. The interest in amorphous drug-polymer solid dispersions has grown due to the potential of improving bioavailability, particularly for poorly water-soluble drugs^{3 - 7}. The basis for this interest stems from the increased rate of dissolution, which can range from hundreds to thousands fold increase, even for the most insoluble active pharmaceutical ingredients³. For drugs whose bioavailability is limited due to poor aqueous solubility (as in BSC class II drugs), the improvement in solubility and hence increase in dissolution rate may lead to enhanced bioavailability^{8 - 11}. Solid dispersion represents a useful pharmaceutical technique for increasing the dissolution, absorption, and therapeutic efficacy of drugs in dosage forms^{12, 13}. The properties, performance, and practical applications of solid dispersions depend on factors such as the method of preparation, composition, selection of a suitable carrier and physicochemical properties of the drug^{1, 14}.

Modafinil is approved by the USFDA for the treatment of narcolepsy, hypersomnia, shift work sleep disorder and excessive daytime sleepiness associated with obstructive sleep apnoea and in adult it is used in attention deficient /hyperactivity disorder (ADHD)¹⁵. It is rapidly absorbed after oral administration with peak plasma concentrations occurring after 2-4 hours. However the oral bioavailability of the drug is poor due to water insolubility¹⁵. Modafinil is BCS class II drug; hence improvement of dissolution will lead to enhancement of bioavailability.

In the present study, to improve water solubility, we prepared solid dispersions of Modafinil using hydrophilic carriers (polyethyleneglycols) by two different methods i.e. melting method and solvent evaporation method. For purposes of comparison, physical mixtures were prepared by simple mixing and homogenization after pulverization of drug and carriers.

MATERIALS AND METHODS

Modafinil was obtained as a gift sample from Alembic Pharmaceuticals Ltd. (India), PEG4000, PEG6000, PEG8000,

carbopol 974, crosspovidone, polyvinylpyrrolidone (PVP) k30, starch, microcrystalline cellulose (MCC), magnesium (Mg.) stearate, acetone and chloroform were purchased from S. D. Fine Chemicals Ltd. (India), and hydrochloric acid was purchased from Loba Chem (India). All other chemicals and reagents used were of AR grade and used without further purifications.

Methods

Preparation of solid dispersions and physical mixtures

Solid dispersions were prepared by two methods i.e. melting method and solvent evaporation method.

Melting method - Solid dispersions containing different mass ratios (1:1, 1:2, 1:4) of drug in PEG4000, PEG6000, and PEG8000 were prepared by melting the carriers in porcelain dish (at around 10 °C above the melting point of carriers) on sand bath, dispersing the drug onto the molten carrier and cooling immediately on freezing mixture of ice and sodium chloride. The solid dispersions were then allowed to cool at an ambient temperature and stored in desiccators for 24 hours. The dry mass was scrapped, crushed and ground in a mortar and passed through sieve #40 (420 µm). The dried mass was stored in desiccator until further use.

Solvent evaporation method - Solid dispersions of same compositions as discussed in previous method were prepared by dissolving required amount of drug and carriers in a solvent mixture of acetone and chloroform (1:1). The solvent was evaporated at 40 °C on a water bath with continuous stirring and the resulting residues were dried under vacuum for 3 hours and stored in desiccators overnight. The dry mass was ground in a mortar, passed through sieve #40 (420 µm) and stored in desiccator until further use.

Physical mixtures were prepared by kneading the desired amount of drug and carriers for 10 minutes and then grounding in mortar with pestle. The co-grinding mixtures were then passed through sieve #40 (420 µm) and stored in desiccator until further use.

Characterisation of solid dispersions

Saturation solubility of Modafinil was determined in mg/ml using UV-visible spectrophotometer (Shimadzu, Japan) measuring maximum absorption (λ_{max}) at 222 nm after filtration and necessary dilutions.

Melting point was determined using precision melting point apparatus (Remi, India).

Stability study of solid dispersions was conducted in stability chamber (Remi, India) at 45 + 2 °C with 75 + 5 % RH for 6 months

and stability was evaluated and compared by determining saturation solubility and melting point.

FTIR spectra of moisture free powdered samples were obtained using a FTIR spectrophotometer (Shimadzu, Japan) in potassium bromide. The scanning range was kept between 400 and 4000 cm^{-1} and the resolution was kept constant at 1 cm^{-1} .

X-ray powder diffraction (XRPD) patterns were recorded on Phillip PW 1130/00 diffractometer (Philips, Holland), employing $\text{CuK}\alpha$ radiation source operating at 30 mA and 40 kV. Samples were scanned from 6 to 40° 2 θ at a scanning rate of 0.02° 2 θ s^{-1} .

Preparation and evaluation of tablets containing Modafinil

Tablets containing solid dispersions, drug-carrier physical mixture or pure drug, equivalent to 200 mg of Modafinil, were prepared by direct compression method after mixing with required amount of different ingredients as shown in Table 4.

All the prepared tablets were subjected to routine quality control tests like hardness & content uniformity and then tested for *in-vitro* dissolution and six months stability.

In-vitro dissolution study of Modafinil was performed on 8 vessel USP type II dissolution test apparatus¹⁶ in 0.1 molL^{-1} hydrochloric acid with constant temperature of 37 + 2 °C and speed at 50 rpm. Aliquots were withdrawn at predetermined time intervals, measured at 222 nm and cumulative percentage release of drug was recorded. Stability study of tablets was conducted in stability chamber (Remi, India) at 45 + 2 °C with 75 + 5 % RH for 6 months and stability was evaluated and compared by determining saturation solubility and melting point.

RESULTS AND DISCUSSION

Solid dispersions of Modafinil were prepared successfully by melting and solvent evaporation method and compared with physical mixtures of drug and carriers. All the prepared formulations were evaluated for saturation solubility and melting point (Table 1, Table 2 and Table 3).

Table 1: Composition and evaluations of solid dispersions prepared by melting method

Batch	Modafinil (mg)	PEG4000 (mg)	PEG6000 (mg)	PEG8000 (mg)	SS (mg mL^{-1})	M_p (°C)
F1	100	100	-	-	1.14	115
F2	100	200	-	-	1.27	113
F3	100	400	-	-	1.59	110
F4	100	-	100	-	1.53	119
F5	100	-	200	-	1.71	117
F6	100	-	400	-	2.12	114
F7	100	-	-	100	1.87	124
F8	100	-	-	200	2.06	122
F9	100	-	-	400	2.58	119

SS=saturation solubility,

Table 2: Composition and evaluations of solid dispersions prepared by solvent evaporation method

Batch	Modafinil (mg)	PEG4000 (mg)	PEG6000 (mg)	PEG8000 (mg)	SS (mg mL^{-1})	M_p (°C)
F10	100	100	-	-	1.03	123
F11	100	200	-	-	1.14	120
F12	100	400	-	-	1.43	118
F13	100	-	100	-	1.37	132
F14	100	-	200	-	1.53	130
F15	100	-	400	-	1.91	127
F16	100	-	-	100	1.67	138
F17	100	-	-	200	1.86	136
F18	100	-	-	400	2.32	132

SS=saturation solubility,

Table 3: Composition and evaluations of physical mixtures

Batch	Modafinil (mg)	PEG4000 (mg)	PEG6000 (mg)	PEG8000 (mg)	SS (mg mL^{-1})	M_p (°C)
F19	100	100	-	-	0.39	163
F20	100	200	-	-	0.43	161
F21	100	400	-	-	0.54	160
F22	100	-	100	-	0.41	165
F23	100	-	200	-	0.46	163
F24	100	-	400	-	0.57	161
F25	100	-	-	100	0.44	165
F26	100	-	-	200	0.50	164
F27	100	-	-	400	0.62	162

SS=saturation solubility,

It was observed in the present study that the solubility of Modafinil was increased with increased proportion of hydrophilic carriers. This might be due to the improved wetting of surface of drug particles by hydrophilic carrier due to which the particle surface became hydrophilic. Higher solubility enhancement was observed with PEG8000 than PEG4000 and PEG6000 due to some unknown cause but might be due to the similar melting behavior and crystalline properties of PEG8000 and Modafinil which led to perfect solution of drug into carrier.

Batch F9 in melting method and F18 in solvent evaporation method has shown highest improvement in solubility of Modafinil. However

batch F9 was selected for further study because the saturation solubility of Modafinil was greater in batch F9 (2.58 mg mL^{-1}) as compared to F18 (2.32 mg mL^{-1}).

Batch F9 was characterized by FTIR (Fig. 1) and XRPD (Fig. 2) to understand possible mechanism of solubility enhancement. Physical mixture batch F27 was also characterized and compared with batch F9 to understand the mechanism of solubility enhancement of Modafinil.

FTIR spectra (Fig. 1) showing characteristic peaks of Modafinil at 3307 and 3167 cm^{-1} for Aliphatic -NH stretching hydrogen bond; 3069 and 3027 cm^{-1} for aromatic -CH stretching; 2976 and 2926 cm^{-1}

¹ for aliphatic -CH stretching; 1685 cm^{-1} for -C=O of amide and 1080 cm^{-1} for -S=O groups. PEG8000 showed characteristic peaks at 3436 cm^{-1} for -OH stretching and at 2890 cm^{-1} for -CH stretching of CH_2 groups. In spectra of batch F9, peaks at 3307 and 3167 cm^{-1} are absent, or rather split into 3337 and 2888 cm^{-1} due to breaking of hydrogen bond between -NH and -CH stretching to form the bond between -NH group of Modafinil with -OH group of PEG8000. Also the intensity of peak at 1686 cm^{-1} was decreased and a peak at 1080 cm^{-1} in pure drug was shifted to 1060 cm^{-1} in solid dispersion indicating absence of free drug in solid dispersion.

It was observed in XRPD diffractogram (Fig. 2) that Modafinil is crystalline in nature showing at least three intense peaks along with several small to intermediate peaks in diffractogram and PEG8000 is semi-crystalline showing two intense peaks in diffractogram. Solid dispersions showed no intense peaks but only few peaks of lesser intensity when compared to pure drug and carrier. This study confirmed that Modafinil was converted in amorphous state in solid dispersion F9 which led to solubility enhancement. In diffractogram of physical mixture (batch F27), reduction of number of peaks as

well as intensity of peaks was observed confirming only partial conversion of crystalline to amorphous form.

All the three tablet batches were characterised for *in-vitro* drug dissolution and six months stability (Table 5). The solid dispersion F9 and physical mixture F27 were also studied for six months stability by taking melting point and saturation solubility as evaluation parameters (Table 5).

It was observed that, melting point of solid dispersion (batch F9) was increased by 9.2 % as compared to 1.2 % and 0.6 % in physical mixture (batch F27) and conventional tablet (batch CT) respectively, suggested stability problem in solid dispersion. Saturation solubility was decreased by 27.9 % in batch F9 as compared to 3.2 % and 3.0 % in batch F27 and batch CT respectively. Similarly cumulative percent drug release was decreased by 27.8 % in batch F9 as compared to 11.7 % and 6.0 % in batch F27 and batch CT respectively. This data strongly suggested poor stability of solid dispersion or the amorphous form. Hence stabilization of solid dispersion was needed to make this formulation strategy successful.




Fig. 1: FTIR spectra of a) Modafinil, b) PEG8000, c) SD batch F9 and d) PM batch F27




Fig. 2: X-ray powder diffraction spectra of a) Modafinil, b) PEG8000, c) SD batch F9 and d) PM batch F27

Batch F9 was formulated as tablet and extensively evaluated for *in-vitro* dissolution and stability study. Tablet containing batch F27 was prepared to understand the effect of simple mixing and tablet containing pure drug was prepared to understand magnitude of improvement in dissolution rate.

Table 4: Composition of tablet containing pure drug, solid dispersion and physical mixture

Tablet ingredients	Batch TF9	Batch TF27	Batch CT
Modafinil (100 MG) + PEG (400 mg)	500	500	100
Carbopol 974 (mg)	120	120	120
Crosspovidone (mg)	24	24	24
PVP K30 (mg)	40	40	40
Starch (mg)	80	80	80
MCC (mg)	20	20	420
Mg. Stearate (mg)	16	16	16
Total (mg)	800	800	800
Content uniformity* (% + SD)	98.55 + 1.24	99.61 + 2.85	97.95 + 0.42

*n=6; Batch TF9, TF27 and CT are coded for tablet of batch F9, batch F27 and conventional tablet respectively.

Table 5: Stability data for six months

Batches	Melting point (°C)		Saturation solubility (mg mL ⁻¹)		Cumulative percentage drug release after 1 hour	
	0 m	6 m	0 m	6 m	0 m	6 m
F9/TF9 ^{a, b}	119	131	2.58	1.86	92.79	67.04
F27/TF27 ^{a, b}	162	164	0.62	0.60	57.93	51.24
drug/CT ^{a, b}	166	165	0.067	0.065	46.34	43.55

n=3, values shown above are average of three determinations with % SD less than 4.5 %.

^amelting point and saturation solubility data is that of batch F9, F27 and pure drug;

^bCumulative percentage drug release after 1 hour data is of batch TF9, TF27 and CT.

CONCLUSIONS

Solid dispersions of Modafinil prepared with different polyethyleneglycols (PEG4000, PEG6000 and PEG8000) by melting and solvent evaporation method resulted in increased saturation solubility of Modafinil. As demonstrated by characterization of solid dispersion by FTIR and XRPD study, a decreased crystallinity of Modafinil as well as modification in surface morphology of Modafinil due to coating of hydrophilic carrier (PEG) can explain the enhanced solubility and improved dissolution rate. This study conclusively demonstrated that solid dispersion can be utilized successfully to improve dissolution profile of poorly water soluble drug after stabilizing the solid dispersions with suitable method.

ACKNOWLEDGEMENT

The authors acknowledge Alembic Pharmaceuticals Ltd. for providing Modafinil as a gift sample.

REFERENCE

1. Chiou WL and Riegelman S. Pharmaceutical applications of solid dispersion systems. *J Pharm Sci* 1971; 60:1281-1302.
2. Ford JL. The current status of solid dispersions. *Pharm Acta Helv* 1986; 61:69-88.
3. Leuner C and Dressman J. Improving drug solubility for oral delivery using solid dispersions. *Eur J Pharm Biopharm* 2000; 50:47-60.
4. Craig DQM. The mechanism of drug release from solid dispersions in water soluble polymers. *Int J Pharm* 2002; 231:131-144.
5. Hancock BC. Disordered drug delivery: destiny, dynamics and the Deborah number. *J Pharm Pharmacol* 2002; 54:737-746.
6. Ahuja N, Katare OP and Singh B. Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. *Eur J Pharm Biopharm* 2007; 65:26-38.
7. Vippagunta SR, Wang Z and Hornung S, Krill S. Factors affecting the formation of eutectic solid dispersions and their dissolution behavior. *J Pharm Sci* 2007; 96:294-304.
8. Ambike AA, Mahadik KT and Paradkar A. Spray-dried amorphous solid dispersions of simvastatin, a low Tg drug: in-vitro and in vivo evaluations. *Pharm Res* 2005; 22:990-998.
9. Khawam A and Flanagan D. Solid-state kinetic model: basics and mathematical fundamentals. *J Phys Chem B* 2006; 110:17315-17328.
10. Marsac PJ, Konno H and Taylor LS. A comparison of the physical stability of amorphous felodipine and nifedipine systems. *Pharm Res* 2006a; 23:2306-2315.
11. Marsac PJ, Shamblin SL and Taylor LS. Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. *Pharm Res* 2006b; 23:2417-2426.
12. Mayersohn M and Gibaldi M. New method of solid state dispersion for increasing dissolution rates. *J Pharm Sci* 1966; 55:1323-1324.
13. Chiou WL and Riegelman S. Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. *J Pharm Sci* 1969; 60:1281-1302.
14. Hajratwala BR. Dissolution of solid dispersion systems. *Aust J Pharm Sci* 1974; NS3:101-109.
15. Minzenberg MJ and Carter CS. Modafinil: A Review of Neurochemical Actions and Effects on Cognition. *Neuropsychopharmacology* 2007; 33:1-26.
16. The United State Pharmacopeia (USP), Asian edition, USP XXVIII 2005; 2412-2414.